J Neurooncol. 2021 Dec 01; doi: 10.1007/s11060-021-03909-1. Epub 2021 Dec 01.

Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma.

Journal of neuro-oncology

Nalee Kim, Do Hoon Lim, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim

PMID: 34853952 DOI: 10.1007/s11060-021-03909-1

Abstract

INTRODUCTION: To date, there is no relevant data supporting the role of salvage radiotherapy (sRT) in patients with refractory or relapsed primary central nervous system lymphoma (PCNSL). Herein, we aimed to investigate the impact of sRT in patients with refractory or relapsed PCNSL following upfront HD-MTX.

METHODS: We retrospectively reviewed 89 patients who had refractory (n = 16) or recurrent disease after an initial favorable response (n = 73); among them, 41 were treated with sRT and 48 were treated without sRT (nRT). Event-free survival (rEFS) and overall survival (rOS) after first recurrence were considered from the date of recurrence to date of each event.

RESULTS: Overall, the first failure was diagnosed at a median of 11.0 months [interquartile range (IQR), 5.6-26.4] after first treatment. More than half of the patients had recurrent disease involving initial tumor bed (n = 47), deep structure (n = 67), and multiple lesions (n = 58). Among 19 patients who were initially treated with 23.4 Gy of whole brain RT, 10 patients received sRT as a re-irradiation; other 31 patients in sRT group were RT naïve patients. There was no significant difference in tumor characteristics between sRT and nRT group. Overall and complete response after salvage treatment were 80% and 48%, respectively; sRT provided higher overall response rate than nRT (93% vs. 69%, p = 0.011). With a median follow-up of 14.3 months (IQR, 7.9-31.4), 2-year rEFS and rOS rates were 27% and 57%, respectively. There were no differences in rEFS and rOS according to sRT (sRT vs. nRT, 26% vs. 28%, p = 0.730; 63% vs. 50%, p = 0.690). Poor performance, recurrence interval < 8 months, and unfavorable response following salvage treatment were associated with inferior rEFS and rOS. Additionally, sRT and stem cell transplantation improved response rate independently after multivariate analysis for complete/partial response.

CONCLUSIONS: We found favorable response rate and comparable survival outcomes following sRT compared with non-local treatments for patients with refractory/relapsed PCNSL. Further studies of patient selection could stratify patients who can benefit from sRT.

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Keywords: Central nervous system; Lymphoma; Radiation therapy; Recurrent disease

References

1. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036–1047. https://doi.org/10.1016/s1470-2045(10)70229-1 - PubMed
2. Lee TH, Lee JH, Chang JH, Ye S-J, Kim TM, Park C-K, Kim IH, Kim BH, Wee CW (2020) Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. Radiat Oncol J 38:35–43. https://doi.org/10.3857/roj.2020.00052 - PubMed
3. Kim JE, Yoon DH, Kim S, Lee DH, Kim JH, Yoon YH, Chi HS, Lee SW, Park CS, Huh J, Suh C (2012) Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma. Korean J Hematol 47:60–66. https://doi.org/10.5045/kjh.2012.47.1.60 - PubMed
4. Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80:159–165. https://doi.org/10.1007/s11060-006-9165-6 - PubMed
5. Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94:e1027–e1039. https://doi.org/10.1212/wnl.0000000000008900 - PubMed
6. Holdhoff M, Wagner-Johnston N, Roschewski M (2020) Systemic approach to recurrent primary CNS lymphoma: perspective on current and emerging treatment strategies. Onco Targets Ther 13:8323–8335. https://doi.org/10.2147/ott.S192379 - PubMed
7. Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410–2418. https://doi.org/10.1200/jco.2017.72.7602 - PubMed
8. Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT (2016) The role of whole brain radiation in primary CNS lymphoma. Blood 128:32–36. https://doi.org/10.1182/blood-2016-01-650101 - PubMed
9. Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823–833. https://doi.org/10.1200/jco.18.00306 - PubMed
10. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol 4:e510–e523. https://doi.org/10.1016/s2352-3026(17)30174-6 - PubMed
11. Kim N, Lim DH, Yoon SE, Kim SJ, Kim WS (2021) Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy. J Neurooncol 154:207–217. https://doi.org/10.1007/s11060-021-03815-6 - PubMed
12. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23:1507–1513. https://doi.org/10.1200/jco.2005.01.161 - PubMed
13. Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69:1178–1182. https://doi.org/10.1212/01.wnl.0000276986.19602.c1 - PubMed
14. Khimani NB, Ng AK, Chen YH, Catalano P, Silver B, Mauch PM (2011) Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy. Ann Oncol 22:979–984. https://doi.org/10.1093/annonc/mdq548 - PubMed
15. Miyakita Y, Ohno M, Takahashi M, Muragaki Y, Katai H, Narita Y (2017) Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL). Jpn J Clin Oncol 47:919–924. https://doi.org/10.1093/jjco/hyx095 - PubMed
16. Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T (2018) Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 100:652–669. https://doi.org/10.1016/j.ijrobp.2017.12.005 - PubMed
17. Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquières H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond V (2012) Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 97:1751–1756. https://doi.org/10.3324/haematol.2011.060434 - PubMed
18. Bromberg JE, Doorduijn JK, Illerhaus G, Jahnke K, Korfel A, Fischer L, Fritsch K, Kuittinen O, Issa S, van Montfort C, van den Bent MJ (2013) Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation–an international primary central nervous system lymphoma study group project. Haematologica 98:808–813. https://doi.org/10.3324/haematol.2012.070839 - PubMed
19. Choi MK, Kang ES, Kim DW, Ko YH, Seok H, Park JH, Pyo DH, Hoon Lim D, Kim SJ, Kim WS (2013) Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. Int J Hematol 98:346–354. https://doi.org/10.1007/s12185-013-1403-z - PubMed
20. Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G (2017) High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German cooperative PCNSL study group. Leukemia 31:2623–2629. https://doi.org/10.1038/leu.2017.170 - PubMed
21. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: société française de greffe de moëlle osseuse-thérapie cellulaire. J Clin Oncol 26:2512–2518. https://doi.org/10.1200/jco.2007.13.5533 - PubMed
22. Lee SC, Kim SJ, Lee DH, Kim WS, Suh C, Won JH (2010) Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 45:801–802. https://doi.org/10.1038/bmt.2009.240 - PubMed
23. Shibamoto Y, Hayabuchi N, Hiratsuka J, Tokumaru S, Shirato H, Sougawa M, Oya N, Uematsu Y, Hiraoka M (2003) Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97:128–133. https://doi.org/10.1002/cncr.11035 - PubMed
24. Iwabuchi M, Shibamoto Y, Sugie C, Ayakawa S, Ogino H, Baba F (2016) Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience. J Radiat Res 57:164–168. https://doi.org/10.1093/jrr/rrv085 - PubMed
25. Kumar R, Laack N, Pollock BE, Link M, O’Neill BP, Parney IF (2015) Stereotactic radiosurgery in the treatment of recurrent CNS lymphoma. World Neurosurg 84:390–397. https://doi.org/10.1016/j.wneu.2015.03.062 - PubMed
26. Kenai H, Yamashita M, Nakamura T, Asano T, Momii Y, Nagatomi H (2006) Gamma Knife surgery for primary central nervous system lymphoma: usefulness as palliative local tumor control. J Neurosurg. https://doi.org/10.3171/sup.2006.105.7.133 - PubMed
27. Sakamoto M, Oya N, Mizowaki T, Araki N, Nagata Y, Takayama K, Takahashi JA, Kano H, Katsuki T, Hashimioto N, Hiraoka M (2006) Initial experiences of palliative stereotactic radiosurgery for recurrent brain lymphomas. J Neurooncol 77:53–58. https://doi.org/10.1007/s11060-005-7698-8 - PubMed

Publication Types

• Journal Article